Fox Chase Cancer Center News

PHILADELPHIA (August 31, 2021)—Researchers at Fox Chase Cancer Center have developed a protocol for procedures to isolate and purify differentiated tumor cells from medulloblastoma in mice and precisely inject these live tumor cells into mouse cerebella.

PHILADELPHIA (August 27, 2021)—Researchers at Fox Chase Cancer Center recently published a study that found that lower levels of trust in community and healthcare sources plays a role in uptake of the vaccine for the human papillomavirus (HPV) vaccine among racial and ethnic minorities in the United States.

PHILADELPHIA (August 24, 2021)—Fox Chase Cancer Center and the Marvin and Concetta Greenberg Pancreatic Cancer Institute were recently renewed as a Clinical Center of Excellence and named for the first time as an Academic Center of Excellence for Pancreatic Cancer by the National Pancreas Foundation.

PHILADELPHIA (August 23, 2021)—Fox Chase Cancer Center is proud to announce the opening of a new Prostate & Urologic Cancer Program at its Fox Chase Cancer Center East Norriton - Hospital Outpatient Center.

PHILADELPHIA (August 18, 2021)—Fox Chase Cancer Center researcher Camille Ragin, PhD, MPH, was recently awarded a Specialized Program of Research Excellence (SPORE) grant of $50,000 for a pilot project examining differences in risk and disease course for Black versus white head and neck cancer patients.

PHILADELPHIA (August 17, 2021) - Fox Chase Cancer Center is proud to be a local sponsor and continued supporter of the annual Miles for Melanoma Philadelphia 5K, which will take place both in person and online this year.

PHILADELPHIA (August 13, 2021) – Fox Chase Cancer Center researcher Camille Ragin, PhD, MPH, has been appointed chair of the Cancer, Heart, and Sleep Epidemiology B Study Section, a committee that will review grant applications submitted to the National Institutes of Health (NIH).

PHILADELPHIA (August 12, 2021) – Namrata “Neena” Vijayvergia, MD, assistant chief of Gastrointestinal Medical Oncology at Fox Chase Cancer Center, has received funding from the National Comprehensive Cancer Network (NCCN) to evaluate neratinib, also known by its brand name Nerlynx, in combination with another drug for the treatment of refractory gastric and esophageal cancer.